A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Clinical trial NCT06455202 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06455202
- Sponsor
- Celldex Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-19
- Primary completion
- 2026-10-01
- Enrollment
- 976
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.